Mouse Monoclonal Androgenreceptor Antibody

The androgen receptor (AR) is a ligand-activated nuclear receptor superfamily member that mediates the biological effects of androgens, such as testosterone and dihydrotestosterone (DHT). Upon ligand binding, AR translocates to the nucleus, binds DNA at androgen-response elements, and regulates gene transcription critical for male sexual development, fertility, and secondary sexual characteristics. AR antibodies are essential tools for studying AR expression, localization, and function in research and diagnostics. These antibodies target specific epitopes within AR's modular structure, including the N-terminal transactivation domain, DNA-binding domain (DBD), hinge region, and ligand-binding domain (LBD). They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess AR levels in tissues, particularly in prostate cancer, where AR signaling drives tumor progression. Aberrant AR activity is also implicated in androgen insensitivity syndrome, spinal and bulbar muscular atrophy (Kennedy’s disease), and other endocrine disorders. Monoclonal AR antibodies offer high specificity for standardized assays, while polyclonal variants may detect multiple epitopes, aiding in conformational studies. Validation across species (human, mouse, rat) and applications (e.g., detecting full-length AR or splice variants like AR-V7) is critical for experimental accuracy. Clinically, AR antibody-based assays help stratify prostate cancer subtypes, predict therapeutic responses, and monitor resistance to anti-androgen therapies, underscoring their translational relevance in precision oncology.